MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1410345

Медицинская библиотека · The New England journal of medicine · 2015

AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.

Heald Alison E, Charleston Jay S, Iversen Patrick L, Warren Travis K, Saoud Jay B, Al-Ibrahim Mohamed, Wells Jay, Warfield Kelly L, Swenson Dana L, Welch Lisa S, Sazani Peter, Wong Michael, Berry Diane, Kaye Edward M, Bavari Sina

СтатьяРандомизированное исследованиеПоддержка правительства СШАПеревод в очереди

Аннотация

BACKGROUND

AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges that targets the viral messenger RNA that encodes Marburg virus (MARV) nucleoprotein. Its safety in humans is undetermined.

METHODS

We assessed the efficacy of AVI-7288 in a series of studies involving a lethal challenge with MARV in nonhuman primates. The safety of AVI-7288 was evaluated in a randomized, multiple-ascending-dose study in which 40 healthy humans (8 humans per dose group) received 14 once-daily infusions of AVI-7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight) or placebo, in a 3:1 ratio. We estimated the protective dose in humans by comparing pharmacokinetic variables in infected nonhuman primates, uninfected nonhuman primates, and uninfected humans.

RESULTS

Survival in infected nonhuman primates was dose-dependent, with survival rates of 0%, 30%, 59%, 87%, 100%, and 100% among monkeys treated with 0 mg, 3.75 mg, 7.5 mg, 15 mg, 20 mg, and 30 mg of AVI-7288 per kilogram, respectively (P<0.001 with the use of the log-rank test for the comparison of survival across groups). No safety concern was identified at doses up to 16 mg per kilogram per day in humans. No serious adverse events were reported. Drug exposure (the area under the curve) was dose-dependent in both nonhuman primates and humans; drug clearance was independent of dose but was higher in nonhuman primates than in humans. The protective dose in humans was initially estimated, on the basis of exposure, to be 9.6 mg per kilogram per day (95% confidence interval, 6.6 to 12.5) for 14 days. Monte Carlo simulations supported a dose of 11 mg per kilogram per day to match the geometric mean protective exposure in nonhuman primates.

CONCLUSIONS

This study shows that, on the basis of efficacy in nonhuman primates and pharmacokinetic data in humans, AVI-7288 has potential as postexposure prophylaxis for MARV infection in humans. (Funded by the Department of Defense; ClinicalTrials.gov number, NCT01566877.).

Для цитирования: Heald Alison E, Charleston Jay S, Iversen Patrick L, Warren Travis K, Saoud Jay B, Al-Ibrahim Mohamed, Wells Jay, Warfield Kelly L, Swenson Dana L, Welch Lisa S, Sazani Peter, Wong Michael, Berry Diane, Kaye Edward M, Bavari Sina. AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.. The New England journal of medicine. 2015. DOI: 10.1056/nejmoa1410345.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.